Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to comprehend and sign an IRB approved Informed Consent Form
Male or female 18 years of age or older
Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an intrauterine device (IUD) and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment and during the course of the study
Previously received and tolerated panitumumab treatment on studies 20020374 Part 2 or 20030138/20040116
Is considered "stable" or "responding" based on the RECIST (20020374 Part 2) or WHO (20040116) criteria, at the final treatment visit of the previous panitumumab clinical trial and the screening visit for this study
No more than 2 months (60 days) have elapsed since the final treatment visit of the previous panitumumab clinical trial
Karnofsky score \> or = 70%
Known to be HIV positive
History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study drug administration
Allergy to the ingredients of the study medication or to Staphylococcus Protein A
History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis
You may not be if
Brain metastases (20040116 patients are allowed only if controlled and asymptomatic)
Uncontrolled hypercalcemia (calcium level outside the upper limit of normal; antihypercalcemic treatment is allowed). Exception: Patients in the Motzer Intermediate Risk Group from 20020374 Cohort 2 with uncontrolled high corrected calcium (\>10 mg/dl) may be enrolled
Use of any anti-tumor therapy or investigational drug, other than panitumumab, between the last visit of the previous panitumumab study and the initial visit in this 20020375 study
Prior treatment with another anti-EGFr agent, other than panitumumab
Myocardial infarction within 1 year prior to entering the study
Has other cancer that has been active and required treatment within the past 5 years (basal cell carcinoma or cervical carcinoma in situ are allowed)
Clareo Health | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
